Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Pseudomonas Infection Clinical Presentation

  • Author: Selina SP Chen, MD, MPH; Chief Editor: Russell W Steele, MD  more...
 
Updated: Mar 09, 2016
 

History

Pseudomonas aeruginosa is so ubiquitous in the hospital environment that distinguishing infection from colonization is often difficult. Furthermore, symptoms are often identical to those observed in other gram-negative infections. As a result, clinical evidence of infection should accompany any culture of the organism at a potential infection site. P aeruginosa reportedly emits a characteristic sweet odor. P aeruginosa is responsible for a broad spectrum of disease, including the following types of infections:

  • AIDS-related infections
  • Bacteremia and sepsis
    • Fever is often the initial symptom. Some patients may also present with tachypnea or tachycardia.
    • Hypotension and shock may develop.
    • Jaundice may occur.
    • Suspect pseudomonal bacteremia in individuals who are immunocompromised (including neonates), who have an extended hospitalization, who have received prolonged antibiotic administration or multiple antibiotics, or who have indwelling catheters.
  • Febrile neutropenia
  • Bone and joint infection (eg, osteochondritis, osteomyelitis, pyarthrosis)
    • Infections of the bones and joints typically result from hematogenous spread from another primary site. This may occur in individuals who have used intravenous (IV) drugs and who have associated urinary tract infections (UTIs) or pelvic infections, in those with penetrating trauma, in postsurgical patients, in those with primary soft tissue infection, and in patients with diabetes or rheumatoid disease.
    • Patients (especially children) may present with osteochondritis after a puncture of the foot through a sneaker or tennis shoe.
    • The sternoclavicular and sacroiliac joints, vertebra, and symphysis pubis are typically involved in individuals who have used IV drugs.
    • Postsurgical patients tend to develop infections in the long bones, especially patients who underwent internal fixation for open fractures. Vertebral osteomyelitis is occasionally observed as a complication of UTI and genitourinary (GU) surgery or instrumentation. Because of vascular insufficiency in the lower extremities of patients with diabetes, they may develop osteomyelitis of the foot. Patients with rheumatoid disease may develop infections in large synovial joints.
    • Children who present with osteochondritis typically experience pain and edema 3-4 days following a puncture wound, only to have symptoms recur or worsen later. Symptoms usually persist more than 1 week without any systemic signs or fever.
    • Sternoarticular pyarthrosis, often seen in individuals who abuse IV drugs, is usually associated with endocarditis, although the primary site is often indiscernible. Joint involvement is typically monoarticular. Complaints include fever, pain, and restricted movement of the shoulder, with limited-to-severe anterior chest pain over the affected joint.
    • Patients with vertebral osteomyelitis can present with pain that persists from weeks to months, especially in the neck or back region. Fever and constitutional symptoms are relatively rare.
    • Chronic contiguous osteomyelitis commonly occurs after a compound fracture or as a complication of surgery for closed fracture of the long bones. It occasionally occurs after a foot puncture wound, as an extension of infection of ischemic ulcers in patients with peripheral vascular disease, following cardiac surgery, and as a complication of peripheral neuropathy associated with pressure necrosis of skin and soft tissue.
  • Skin and soft tissue infections (eg, burn wound sepsis, dermatitis, ecthyma gangrenosum [EG], pyoderma, cellulitis, hot tub folliculitis, necrotizing fasciitis, chronic paronychia)
    • Do not confuse EG with pyoderma gangrenosum or streptococcal ecthyma; EG is a rare but pathognomonic form of pseudomonal infection. Although EG is often due to Pseudomonas, case reports indicate that the same frequency is associated with non-Pseudomonas EG (ie, Fusarium, Klebsiella).
    • EG in patients without neutropenia is very rare, as is nonbacteremic EG cases. However, nonsepticemic cases occur in patients without immunosuppression or neutropenia or following antibiotic therapy.
    • Pseudomonal burn wound infections occur with systemic involvement (eg, bacteremia, fever, hypothermia, disorientation, obtundation, hypotension, oliguria, ileus, leukopenia).
    • Chronic paronychia slowly evolves and initially presents with tenderness and mild swelling about the proximal and lateral nail folds.
    • Pseudomonal toe web infections are distinctive clinical entities often misdiagnosed as tinea pedis. Dried exudate or a green stain (caused by pyoverdin) may be found on socks or toenails.
    • Pseudomonal folliculitis presents as cutaneous lesions any time from 8 hours to 5 days or more (mean incubation period is 48 h) after using a contaminated whirlpool, home hot tub, water slide, physiotherapy pool, or contaminated loofah sponge. Malaise and fatigue may occur during initial days of the eruption. Fever (uncommon) is low grade when present.
    • Localized cellulitis can occur as a secondary infection of tinea of the toe webs or groin; from bedsores, stasis ulcers, or burns; in grafted areas; or under the foreskin of the penis. Maceration or occlusion of these skin lesions leads to secondary infection. Deep erosions and tissue necrosis may occur before the condition is diagnosed correctly. Severe pain is highly characteristic of an evolving infection.
  • CNS infection (eg, brain abscess, meningitis)
    • CNS infections are more common among patients who are immunocompromised or in patients who recently have undergone a neurosurgical procedure.
    • P aeruginosa has been isolated with increasing frequency in older patients with meningitis, but pseudomonal infections rarely cause neonatal meningitis.
    • Clinical symptoms are indistinguishable from other forms of bacterial meningitis. Symptoms can be nonspecific (eg, headache, fever, nausea, vomiting, disorientation, lethargy, stiff neck).
    • Often, CNS involvement is due to a complication from another site (eg, malignant external otitis). Although CNS complications are rare, they are often fatal. These include meningitis, brain abscess, and dural sinus thrombophlebitis.
  • Ear infections (eg, otitis media, chronic suppurative otitis media, otitis externa, malignant external otitis)
    • Involvement of the ear can present as a mild, superficial, and often self-limited infection (eg, swimmer ear) or as malignant otitis externa. Early stages of swimmer's ear are characterized by erythema, edema, accumulation of debris in the canal, and, sometimes, pain. As the disease progresses, the erythema radiates into the pinna, and purulent material partly obstructs the ear, exuding from the canal.
    • More than 95% of cases of malignant external otitis are caused by P aeruginosa. Clinical presentation starts with a history of nonresolving otitis externa, especially in patients who have diabetes or AIDS. Patients present with severe ear pain (otalgia) that worsens at night and a purulent discharge (otorrhea). The pinna may be involved. As the disease progresses, osteomyelitis of the base of the skull and temporomandibular joint osteomyelitis can occur.
    • Children with malignant external otitis have a higher incidence of facial palsy because of underdevelopment of their mastoid process and because of the more medial location of the fissures of Santorini, placing the facial nerve closer to the ear canal. The glossopharyngeal, vagal, spinal accessory, and hypoglossal nerves can be involved. The trigeminal and abducens nerves are rarely affected, and optic nerve involvement has been reported. Involvement of the olfactory, oculomotor, and trochlear nerves has not been reported.
  • Eye infections (eg, endophthalmitis, keratitis, ophthalmia neonatorum, blepharoconjunctivitis, scleral abscess, orbital cellulitis)
    • Although pseudomonal eye infections are often associated with hydrophilic contact lens wear, infections have also been reported in patients who do not wear contact lenses.
    • Pseudomonal keratitis can present as a rapidly developing, necrotic, grayish stromal infiltrate in a bed of epithelial injury and surrounding edema. Disease progression varies but can rapidly progress and involve the entire cornea within 48 hours, leading to perforation. Fever and systemic symptoms are usually absent.
    • Pseudomonal corneal ulcers may lead to rapid loss of visual function and are considered a medical emergency.
    • Pseudomonal endophthalmitis progresses more rapidly than other bacterial infections. Clinical features may include pain, conjunctival hyperemia, chemosis, lid edema, decreased visual acuity, hypopyon, or severe anterior uveitis with involvement of the vitreous and panophthalmitis.
  • GI infections (eg, epidemic diarrhea, necrotizing enterocolitis (NEC), typhlitis, rectal abscess, Shanghai fever)
    • Presentation is indistinguishable from other bacteremic GI infections.
    • Neonates may present with NEC.
    • Those with hematological malignancies may develop typhlitis or a rectal abscess.
    • Epidemics of pseudomonal diarrheal diseases occur in children.
  • GU infections (eg, epididymitis, prostatitis, urethritis, UTIs): The clinical presentation of pseudomonal UTIs is indistinguishable from other bacterial UTIs.
  • Cardiovascular (CV) infections (eg, endocarditis, pericarditis, cardiac tamponade)
    • Pseudomonal infectious endocarditis (IE) affects normal and abnormal valves on both sides of the heart, resulting in valve destruction and heart failure. Biventricular and multiple valve infections are common in pseudomonal IE.
    • This organism has been isolated in patients with IE who abuse IV drugs, specifically pentazocine and tripelennamine (ie, "Ts" and "blues"). Individuals who abuse pentazocine and tripelennamine have a propensity for right-sided IE.
    • Fever is the most common symptom
  • Respiratory infections (eg, primary or nonbacteremic, bacteremic, colonization, and nosocomial pneumonia, lower respiratory tract infections of cystic fibrosis [CF], ventilator-associated pneumonia [VAP])
    • Symptoms in patients with CF vary from frequent upper respiratory tract infections (URTIs) and a persistent cough after each bout to recurrent episodes of pneumonia, with or without a lingering cough between exacerbations.
    • Initial age of initiation of Pseudomonas is affected by genotype functional class but not in lifestyle changes (eg, breastfeeding, cigarette smoke).[6] Most patients eventually develop a chronic and increasingly severe productive cough, decreased appetite, weight loss, and diminished activity, particularly during exacerbation.
    • Evidence suggests that chronic P aeruginosa lung infection plays a role in bronchiectasis development. Other symptoms include wheezing, tachypnea, and irritability. Low-grade fever often accompanies exacerbations; high-grade fever is uncommon.
  • Bacteremic pseudomonal pneumonia usually occurs in patients with malignancies (especially malignancies involving the hematopoietic system), in patients who are neutropenic as a result of chemotherapy, and in children and adults with AIDS.
  • Primary or nonbacteremic pneumonia results from aspiration of Pseudomonas species from upper respiratory structures that have been colonized. The disease process is fulminant, usually fatal, and characterized clinically by fever, chills, severe dyspnea, copious and purulent-productive cough, cyanosis, apprehension, mental confusion, and systemic toxicity.
  • Glanders
    • Glanders also occurs in stages, with symptoms depending on the organism's route of infection. Generalized symptoms include fever, muscle aches, chest pain, muscle tightness, and headache. Additional symptoms may include excessive eye tearing, light sensitivity, and diarrhea.
    • Types of infections associated with glanders include the following:
      • Localized infections: From a cut or scratch in the skin, a localized infection with ulceration develops within 1-5 days at the site where the bacteria penetrated the body. Lymph nodes may also be swollen. Infections involving the mucous membranes in the eyes, nose, and respiratory tract cause increased mucus production from the respective sites.
      • Pulmonary infections: These may cause pneumonia, pulmonary abscesses, and pleural effusion. Radiography reveals localized infection in the lobes of the lungs.
      • Bloodstream infections: A bloodstream infection associated with glanders is usually fatal within 7-10 days without any treatment.
      • Chronic infections: The chronic form of glanders involves multiple abscesses within the muscles of the arms and legs or in the spleen or liver.
  • Melioidosis
    • Melioidosis stages include acute, localized, and chronic infections. The incubation period is not clearly defined but may range from 2 days to years.
    • Stages of melioidosis include the following:
      • Acute: Characterized by a localized nodule, caused by inoculation of the bacteria through a break in the skin, which can lead to secondary lymphangitis, regional lymphadenitis, fever, and myalgia. Acute melioidosis may rapidly progress to infect the bloodstream.
      • Pulmonary infection: The clinical picture ranges from mild bronchitis to severe pneumonia. Onset of pulmonary melioidosis is usually associated with high fever, headache, anorexia, and general myalgia. Chest pain is also common. The hallmark is a nonproductive or productive cough with normal sputum.
      • Acute bloodstream infection: Patients with underlying illness (eg, HIV, renal failure, diabetes) are predisposed to this form of the disease, which usually results in septic shock. Symptoms of bloodstream infection vary, depending on the original infection site, but generally include respiratory distress, severe headache, fever, diarrhea, development of pus-filled lesions on the skin, myalgia, and disorientation. The infection typically has short duration, although abscesses form throughout the body.
      • Chronic suppurative infection: Chronic melioidosis is an infection involving several organs, typically including the joints, viscera, lymph nodes, skin, brain, liver, lung, bones, and spleen. Chronic apical lung disease often resembles tuberculosis (TB).
Next

Physical

The clinical presentation of pseudomonal infections depends on the site of infection and is often indistinguishable from other gram-negative organisms.

Glanders and melioidosis infections have different stages with varied clinical presentations.

  • Bacteremia and sepsis
    • Clinical presentation is often identical to other gram-negative organisms.
    • Fever is usually present, except in very young or premature infants. Fever is often accompanied by tachycardia and tachypnea.
    • Patients appear toxic and may present with apprehension, disorientation, or obtundation.
    • Signs of shock, including hypotension, azotemia, or acute renal failure, may be observed.
    • Respiratory failure occurs in the presence of bacteremic pseudomonal pneumonia or in conjunction with airway restrictive disease syndrome.
    • Jaundice appears to occur more often than in other forms of gram-negative sepsis, but disseminated intravascular coagulation (DIC) is relatively uncommon.
    • Skin lesions may be an important distinguishing feature of pseudomonal bacteremia, especially typical EG lesions.
    • A diffuse maculopapular eruption, primarily on the trunk, has also been reported in early stages of pseudomonal sepsis. Metastatic abscesses of the extremities and fingertips occasionally manifest later in the course of the disease.
  • Bone infections
    • Because pseudomonal infections have a predilection for fibrocartilaginous joints of the axial skeleton, determining whether arthritis preceded or resulted from the infection is difficult. The disease process is usually indolent, and it is not as destructive and does not progress as rapidly as other infections.
    • Pseudomonal osteochondritis presents with a superficial area of cellulitis on the plantar surface of the foot; deep palpation reveals slight tenderness.
    • Physical signs of sternoarticular pyarthrosis include erythema, edema, and tenderness over the affected joint, and restricted range of motion of the ipsilateral shoulder.
    • Physical signs in patients with vertebral osteomyelitis include local tenderness and decreased range of motion of the spine. Neurologic deficits, which tend to be mild, occur in approximately 15% of cases.
    • Differentiate between patients with infection of the pubic symphysis and those with osteitis pubis.
  • Skin infections
    • The hallmark lesions resulting from pseudomonal wound infections are multifocal, with dark-brown to black or violaceous discoloration of the burn eschar, and are accompanied by edema and hemorrhagic necrosis.
    • EG lesions are multiple noncontiguous ulcers or solitary ulcers. These lesions begin as isolated, red, purpuric macules that become vesicular, indurated, and, eventually, bullous or pustular. The bullae may be hemorrhagic but contain little if any pus. Lesions can remain localized or, more often, can extend over several centimeters. The central area of these lesions becomes hemorrhagic and necrotic, and then the lesion denudes to form a gangrenous ulcer with a gray-black eschar and erythematous halo. Although lesions can occur anywhere, they occur mainly in the gluteal and perineal regions (57%), the extremities (30%), the trunk (6%), and the face (6%). These skin lesions slowly heal. Patients with septicemia have associated signs that include elevated temperatures, chills, hypotension, tachycardia, and tachypnea.
    • In chronic paronychia, the skin around the nail becomes pale, red, painful, and swollen. A small amount of pus may occasionally be expressed from beneath the proximal nail fold. The nail plate turns green-black, which is characteristic of pseudomonal infections. The conditions cause little discomfort or inflammation. This presentation is often confused with subungual hematoma.
    • A Pseudomonas -infected toe web presents as a thick, white, macerated scale with a green discoloration in the toe webs. The most consistent clinical feature is soggy wet toe webs and adjacent skin. In the mildest form of pseudomonal infection in the toe web, the affected tissue is damp, softened, boggy, and white. The second, third, and fourth toe webs are the most common sites of initial involvement. Severe forms may progress to denuded skin and profuse, serous, or purulent material.
    • Pseudomonal folliculitis presents with a few to more than 50 urticarial plaques that measure 0.5-3 cm in diameter, with a central papule or pustule on all skin surfaces other than the head. The rash can be a polymorphous eruption or a mixture of follicular, maculopapular, vesicular, or pustular lesions. These lesions often are pruritic; most clear in 7-10 days, leaving round spots of red-brown postinflammatory hyperpigmentation. However, some patients may have recurrent crops of lesions over an extended period of 3 months (see the image below).
      Erythematous papulopustules of pseudomonas follicuErythematous papulopustules of pseudomonas folliculitis. Courtesy of Mark Welch, MD.
    • Pseudomonal cellulitis presents with a dusky red–to–bluish green skin discoloration and purulent discharge. The typical fruity or mouselike odor has been linked to pseudomonal infection. Vesicles and pustules may occur as satellite lesions. The eruption may spread to cover wide areas and cause systemic manifestations.
  • CNS infections
    • Clinical signs of pseudomonal meningitis are indistinguishable from bacterial meningitis, except for the hallmark EG skin lesions.
    • Signs of CNS infections in neonates are often nonspecific and subtle (eg, fever, hypothermia, lethargy, seizures, irritability, bulging fontanel, respiratory distress, feeding intolerance, vomiting).
    • In children and adults, physical presentations of bacterial meningitis can include fever, photophobia, nuchal rigidity, lethargy, disorientation, coma, and ataxia.
  • Ear infections
    • Involvement of the ear can be mild to severe.
    • Pain can be elicited by traction of the tragus or pinna, although pain becomes persistent as the disease progresses.
    • Typical presentations include erythema, edema, pain, and warmth; however, many individuals who are immunocompromised may manifest no signs.
  • Eye infections
    • Ring ulcers can reportedly develop.
    • The corneal epithelium peripheral to the primary ulcer typically develops a diffuse, gray, ground-glass appearance. The ulcer is also associated with marked anterior chamber reaction and hypopyon formation.
    • Extensive keratitis can extend to the limbus and produce an infectious scleritis.
    • Diffuse epithelial disease is usually associated with hydrophilic contact lens wear.
  • GI infections
    • Pseudomonal infections can affect the entire alimentary canal, from the oropharynx to the rectum. The clinical presentation is often indolent, except for occasional NEC (in premature infants), typhlitis, hemorrhagic and necrotic ulcers, and abscesses in infants, older children, and adults. Skin manifestations can occur.
    • NEC presents with irritability, signs of dehydration, vomiting, diarrhea, dehydration, abdominal distension, and signs of peritonitis.
    • Diarrheal epidemics can present with mild-to-severe diarrhea, signs of dehydration, and vascular collapse. Pseudomonal infections have also been causally associated with Shanghai fever, a syndrome associated with diarrhea or constipation, rash, and fever persisting as long as 1-2 weeks.
    • The pathological changes observed in patients with typhlitis range from localized lesions in the cecum to necrosis and gangrene with perforation and peritonitis.
    • Although rare, rectal abscesses can spread to the scrotum and penis, leading to Fournier gangrene.
  • GU infections
    • Presentations of pseudomonal UTIs are generally indistinguishable from other bacterial UTIs.
    • One rare exception is development of ulcerative lesions of the bladder mucosa, ureters, and renal pelvis, resulting in sloughing of vesical membrane in the urine.
    • Another rare sequela is the development of multiple renal infarcts.
  • CV infections
    • Endocarditis can present with a cardiac murmur, depending on the valve affected.
    • Skin and soft tissue manifestations (eg, Osler nodes, Janeway lesions) are rare in both right-sided and left-sided diseases.
  • Respiratory infections
    • Physical signs in patients with CF include evidence of undernutrition, increased anteroposterior diameter, retractions, cyanosis, inspiratory and expiratory wheezing, rhonchi, localized or generalized moist rales, abdominal distention, and clubbing of fingers and toes.
    • A rapid progression from pulmonary vascular congestion to pulmonary edema to necrotizing bronchopneumonia occurs in patients with bacteremic pseudomonal infections. Physical signs that can be expected include retraction, crackles, rhonchi, dulled reflexes, fever, and cyanosis.
    • Primary nonbacteremic pseudomonal infections can present as a diffuse bronchopneumonia, which is typically bilateral. Small pleural effusions are common, empyema is rare, and a pattern of lobar consolidation is sometimes noted. Correlating physical signs include crackles, rhonchi, and dulled reflexes at bases.
Previous
Next

Causes

Individuals who are immunocompromised tend to be vulnerable to pseudomonal infections. People who work with animals or who are exposed to contaminated soil and water in certain endemic areas are at risk for glanders and melioidosis.

Risk factors and predisposing conditions include the following:

  • Bacteremia: Conditions that predispose disease progress to bacteremia include hematological malignancies, immunoglobulin deficiency states, neutropenia, diabetes mellitus (DM), organ transplantation, severe burns, diffuse dermatitis, and AIDS. Other predisposing factors include cancer chemotherapy that causes neutropenia or ulceration of the respiratory and GI tracts, steroid administration, antibiotic therapy, placement of IV lines, urinary tract instrumentation or catheterization, surgery, trauma, and premature birth. IV lines should be inserted under sterile conditions and should be changed per hospital protocol.
  • Bone infections: Individuals at risk include persons who abuse IV drugs; postsurgical patients; patients with penetrating trauma, diabetes, peripheral vascular disease, or rheumatoid arthritis; older persons; and patients with chronic debilitation.
  • Skin infections: Pseudomonas species do not grow on dry skin. Patients who are exposed to moisture have an increased risk for skin infections. Separation of the cuticle from the nail plate (ie, onycholysis) leaves the space between the proximal nail fold and nail plate exposed to bacteria, which results in chronic paronychia and pseudomonal toe web. The contamination of healthcare workers' protective gear has been linked to transmission of multidrug-resistant P aeruginosa (17.4%; 95% confidence interval, 9.4-25.4%).[7] People who wear heavy wet boots also are more likely to develop pseudomonal toe web infections. Children have higher risk than adults of developing folliculitis from exposure to Pseudomonas organisms in a contaminated whirlpool, home hot tub, water slide, physiotherapy pool, or contaminated loofah sponge.
  • CNS infections: Pseudomonal meningitis occurs in patients who have had recent neurosurgical procedures or who are immunocompromised. A brain abscess, however, rarely occurs in an immunocompromised host; the risk of brain abscess is higher is patients with otitis media or paranasal sinusitis, and it is a common etiology in older patients. Predisposing factors of neonatal meningitis include maternal infections (especially UTI and uterine infections) and the following obstetrical risk factors:

 

See the list below:

  • Congenital anomalies
  • Perinatal hypoxia or asphyxia
  • Neonates whose treatment included cardiopulmonary resuscitation and monitoring, prolonged ventilatory support, and/or multiple IV line insertions
  • Ear infections: Malignant otitis externa occurs in patients who are older and in patients who have diabetes or AIDS.
  • Eye infections: Contact lens wearers have an increased risk of developing gram-negative infections, including pseudomonal infections. Pseudomonal endophthalmitis may result from penetrating trauma, intraocular surgery, posterior perforation of a corneal ulcer, or hematogenous spread from another primary site.
  • GI infections: Pseudomonal infections can affect every portion of the GI tract. The disease is often underestimated; the highest risk is among young infants, children, and persons with hematological malignancies and chemotherapy-induced neutropenia. Additionally, colonization of the GI tract is an important portal of entry for pseudomonal bacteremia in patients who are neutropenic. The spectrum of disease can range from very mild symptoms to severe NEC with significant morbidity and mortality.
  • GU infections: The greatest risk is among patients who are hospitalized and patients who had urinary tract catheterization, instrumentation, or surgery. These infections can involve the urinary tract through an ascending infection or through bacteremic spread and are a frequent source of bacteremia. An obvious preventive measure is to avoid catheterization. If this is not possible, the catheter should be removed as soon as possible. Catheters should be inserted aseptically under sterile conditions. The most important hygienic measure is handwashing by health care personnel. If a urinary catheter is required for long periods, it should be replaced per hospital protocol. Catheters and the area around the urethra should be cleaned with soap and water daily and after each bowel movement. Prophylactic use of antibiotics is not recommended because it leads to the emergence of resistant strains of bacteria.
  • CV infections: The risk of endocarditis among individuals who abuse IV drugs (ie, 2-5% per person-year) is much greater than the risk for patients with rheumatic heart disease or prosthetic valves. A case report describes an infant with human immunodeficiency virus (HIV) who developed pseudomonal pericarditis and tamponade, which suggests pericardial effusions are more common in patients with HIV than previously recognized.[8]
  • Respiratory infections
    • Lower respiratory tract infections with P aeruginosa occur almost exclusively in persons with compromised respiratory systems, especially patients with CF. Most bacteremic pseudomonal pneumonia occurs in patients with malignancies and immunodeficiencies.
    • Primary nonbacteremic pseudomonal pneumonia occurs in patients who have colonization of Pseudomonas organisms. It can be hospital-associated in the ICU setting and is associated with positive-pressure ventilation and endotracheal tubes.
    • The pneumonia may be primary or may follow aspiration of the organism from the upper respiratory tract, especially in patients on mechanical ventilation. Alternatively, it may occur as a result of bacteremic spread to the lungs.
    • Because Pseudomonas species can multiply in nebulizer fluid, proper cleaning, sterilization, and disinfection of reusable equipment are required.
    • Pseudomonas risk should be considered and appropriate empiric antibiotics should be started in accordance to Core Measure for Pneumonia.
Previous
 
 
Contributor Information and Disclosures
Author

Selina SP Chen, MD, MPH Assistant Professor of Pediatrics, Department of Internal Medicine, John A Burns School of Medicine, University of Hawaii; Internal Medicine and Pediatric Hospitalist, Kapiolani Medical Center for Women and Children; Internal Medicine Hospitalist, Straub Clinic and Hospital; Electronic Medical Record Physician Liaison and Trainer

Selina SP Chen, MD, MPH is a member of the following medical societies: American Academy of Pediatrics, American College of Physicians-American Society of Internal Medicine, Society of Hospital Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Ralph Rudoy, MD 

Ralph Rudoy, MD is a member of the following medical societies: American Academy of Pediatrics, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Larry I Lutwick, MD Professor of Medicine, State University of New York Downstate Medical School; Director, Infectious Diseases, Veterans Affairs New York Harbor Health Care System, Brooklyn Campus

Larry I Lutwick, MD is a member of the following medical societies: American College of Physicians, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Chief Editor

Russell W Steele, MD Clinical Professor, Tulane University School of Medicine; Staff Physician, Ochsner Clinic Foundation

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, Southern Medical Association

Disclosure: Nothing to disclose.

Additional Contributors

Leonard R Krilov, MD Chief of Pediatric Infectious Diseases and International Adoption, Vice Chair, Department of Pediatrics, Winthrop University Hospital; Professor of Pediatrics, Stony Brook University School of Medicine

Leonard R Krilov, MD is a member of the following medical societies: American Academy of Pediatrics, American Pediatric Society, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Society for Pediatric Research

Disclosure: Nothing to disclose.

References
  1. Bendiak GN, Ratjen F. The approach to Pseudomonas aeruginosa in cystic fibrosis. Semin Respir Crit Care Med. 2009 Oct. 30(5):587-95. [Medline].

  2. Pollack M. The Virulence of Pseudomonas aeruginosa. Rev Infect Dis. 1984. 6:S617-26.

  3. Burkholder W. Sour skin, a bacterial rot of onion bulbs. Phytopathology. 1950. 40:115-8.

  4. Werth BJ, Carreno JJ, Reveles KR. Shifting trends in the incidence of Pseudomonas aeruginosa septicemia in hospitalized adults in the United States from 1996-2010. Am J Infect Control. 2015 May 1. 43 (5):465-8. [Medline].

  5. Reichert F, Piening B, Geffers C, Gastmeier P, Bührer C, Schwab F. Pathogen-Specific Clustering of Nosocomial Blood Stream Infections in Very Preterm Infants. Pediatrics. 2016 Mar 8. [Medline].

  6. Rosenfeld M, Emerson J, McNamara S, et al. Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort. J Cyst Fibros. 2012 May 1. [Medline].

  7. Morgan DJ, Rogawski E, Thom KA, et al. Transfer of multidrug-resistant bacteria to healthcare workers' gloves and gowns after patient contact increases with environmental contamination. Crit Care Med. 2012 Apr. 40(4):1045-51. [Medline].

  8. Kielhofner M, Atmar RL, Hamill RJ, Musher DM. Life-threatening Pseudomonas aeruginosa infections in patients with human immunodeficiency virus infection. Clin Infect Dis. 1992 Feb. 14(2):403-11. [Medline].

  9. Giamarellou H, Antoniadou A. Antipseudomonal antibiotics. Med Clin North Am. 2001 Jan. 85(1):19-42, v. [Medline].

  10. [Guideline] Committee on Infectious Diseases. The use of systemic fluoroquinolones. Pediatrics. 2006 Sep. 118(3):1287-92. [Medline].

  11. Douidar SM, Snodgrass WR. Potential role of fluoroquinolones in pediatric infections. Rev Infect Dis. 1989 Nov-Dec. 11(6):878-89. [Medline].

  12. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999 Jun. 43(6):1379-82. [Medline].

  13. Altemeier WA, Tonelli MR, Aitken ML. Pseudomonal pericarditis complicating cystic fibrosis. Pediatr Pulmonol. 1999 Jan. 27(1):62-4. [Medline].

  14. Arbulu A, Holmes RJ, Asfaw I. Tricuspid valvulectomy without replacement. Twenty years' experience. J Thorac Cardiovasc Surg. 1991 Dec. 102(6):917-22. [Medline].

  15. Ashdown LR, Guard RW. The prevalence of human melioidosis in Northern Queensland. Am J Trop Med Hyg. 1984 May. 33(3):474-8. [Medline].

  16. Baltch AL, Griffin PE. Pseudomonas aeruginosa bacteremia: a clinical study of 75 patients. Am J Med Sci. 1977 Sep-Oct. 274(2):119-29. [Medline].

  17. Baum J, Barza M. Topical vs subconjunctival treatment of bacterial corneal ulcers. Ophthalmology. 1983 Feb. 90(2):162-8. [Medline].

  18. Brewer SC. Clinical Investigations in Critical Care: Ventilator-Associated Pneumonia due to Pseudomonas aeruginosa. Chest. 1996. 109:4:1020-30.

  19. Byrne S, Maddison J, Connor P, et al. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. J Antimicrob Chemother. 1995 Jul. 36 Suppl A:135-43. [Medline].

  20. Cleveland RP, Hazlett LD, Leon MA, Berk RS. Role of complement in murine corneal infection caused by Pseudomonas aeruginosa. Invest Ophthalmol Vis Sci. 1983 Feb. 24(2):237-42. [Medline].

  21. Cunha BA. Antibiotic resistance. Med Clin North Am. 2000 Nov. 84(6):1407-29. [Medline].

  22. Davis SD, Sarff LD, Hyndiuk RA. Comparison of therapeutic routes in experimental Pseudomonas keratitis. Am J Ophthalmol. 1979 May. 87(5):710-6. [Medline].

  23. Edgeworth JD, Treacher DF, Eykyn SJ. A 25-year study of nosocomial bacteremia in an adult intensive care unit. Crit Care Med. 1999 Aug. 27(8):1421-8. [Medline].

  24. EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med. 1987 Dec 31. 317(27):1692-8. [Medline].

  25. Fagon JY, Chastre J, Domart Y, et al. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis. 1989 Apr. 139(4):877-84. [Medline].

  26. Germiller JA, El-Kashlan HK, Shah UK. Chronic Pseudomonas infections of cochlear implants. Otol Neurotol. 2005 Mar. 26(2):196-201. [Medline].

  27. Giamarellou H. Empiric therapy for infections in the febrile, neutropenic, compromised host. Med Clin North Am. 1995 May. 79(3):559-80. [Medline].

  28. Giamarellou H. Malignant otitis externa: the therapeutic evolution of a lethal infection. J Antimicrob Chemother. 1992 Dec. 30(6):745-51. [Medline].

  29. Gitterman B. In Brief: Aminoglycosides. Pediatrics in Review. 1998 Aug. 19(8):285.

  30. Griffiths AL, Jamsen K, Carlin JB, et al. Effects of segregation on an epidemic Pseudomonas aeruginosa strain in a cystic fibrosis clinic. Am J Respir Crit Care Med. 2005 May 1. 171(9):1020-5. [Medline].

  31. Harris A, Torres-Viera C, Venkataraman L, et al. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis. 1999 May. 28(5):1128-33. [Medline].

  32. Highsmith AK, Le PN, Khabbaz RF, Munn VP. Characteristics of Pseudomonas aeruginosa isolated from whirlpools and bathers. Infect Control. 1985 Oct. 6(10):407-12. [Medline].

  33. Ho PL, Chan KN, Ip MS, et al. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Chest. 1998 Dec. 114(6):1594-8. [Medline].

  34. Husson MO, Richet H, Aubert A, et al. In vitro comparative activity of meropenem with 15 other antimicrobial agents against 1798 Pseudomonas aeruginosa isolates in a French multicenter study. Clin Microbiol Infect. 1999 Aug. 5(8):499-503. [Medline].

  35. Isles A, Maclusky I, Corey M, et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr. 1984 Feb. 104(2):206-10. [Medline].

  36. Kang CI, Kim SH, Park WB, et al. Clinical features and outcome of patients with community-acquired Pseudomonas aeruginosa bacteraemia. Clin Microbiol Infect. 2005 May. 11(5):415-8. [Medline].

  37. Karlowicz MG, Buescher ES, Surka AE. Fulminant late-onset sepsis in a neonatal intensive care unit, 1988- 1997, and the impact of avoiding empiric vancomycin therapy. Pediatrics. 2000 Dec. 106(6):1387-90. [Medline].

  38. Kerem E. The Role of Pseudomonas aeruginosa in the Pathogenesis of Lung Disease in Cystic Fibrosis: More Questions than Answers. Pediatric Pulmonology- Supplement. 1997. 14:403-11.

  39. Komshian SV, Tablan OC, Palutke W, Reyes MP. Characteristics of left-sided endocarditis due to Pseudomonas aeruginosa in the Detroit Medical Center. Rev Infect Dis. 1990 Jul-Aug. 12(4):693-702. [Medline].

  40. Koprnova J, Beno P, Korcova J, et al. Bacteremia due to Pseudomonas aeruginosa: results from a 3-year national study in the Slovak Republic. J Chemother. 2005 Oct. 17(5):470-6. [Medline].

  41. Lahiri T. Approaches to the treatment of initial Pseudomonas aeruginosa infection in children who have cystic fibrosis. Clin Chest Med. 2007 Jun. 28(2):307-18. [Medline].

  42. Malaty J, Lee JC, Zhang M, et al. Click here to read Hearing loss and extent of labyrinthine injury in Pseudomonas otitis media. Malaty J, Lee JC, Zhang M, Stevens G, Antonelli PJ. Department of Otolaryngology, University of Florida, Gainesville 32610-0264, USA. Otolaryngol Head Neck Surg. 2005 Jan. 132(1):25-9. [Medline].

  43. Malaty J, Lee JC, Zhang M, et al. Hearing loss and extent of labyrinthine injury in Pseudomonas otitis media. Otolaryngol Head Neck Surg. 2005 Jan. 132(1):25-9. [Medline].

  44. Marchetti F, Bua J. More evidence is needed in the antibiotic treatment of Pseudomonas aeruginosa colonisation. Arch Dis Child. 2005 Nov. 90(11):1204. [Medline].

  45. Masekela R, Green RJ. The role of macrolides in childhood non-cystic fibrosis-related bronchiectasis. Mediators Inflamm. 2012. 2012:134605. [Medline]. [Full Text].

  46. Medical Letter. Drugs for sexually transmitted infections. Med Lett Drugs Ther. 1999 Sep 24. 41(1062):85-90. [Medline].

  47. Medical Letter. The choice of antibacterial drugs. Med Lett Drugs Ther. 1999 Oct 22. 41(1064):95-104. [Medline].

  48. Milner SM. Acetic acid to treat Pseudomonas aeruginosa in superficial wounds and burns. Lancet. 1992 Jul 4. 340(8810):61. [Medline].

  49. Morrison AJ Jr, Wenzel RP. Epidemiology of infections due to Pseudomonas aeruginosa. Rev Infect Dis. 1984 Sep-Oct. 6 Suppl 3:S627-42. [Medline].

  50. Mukhopedhyay S, Singh M, Cater JI. Nebulized antipseudomonal antibiotic therapy in cystic fibrosis: A meta-analysis of benefits and risks. Thorax. 1996. 51:364.

  51. Mull, CC. Case Report: Ecthyma gangrenosum as a Manifestation of Pseudomonas Sepsis in a Previously Healthy Child. Annals Emerg Med. 2000 Oct. 36:4.

  52. Nagaki M, Shimura S, Tanno Y, et al. Role of chronic Pseudomonas aeruginosa infection in the development of bronchiectasis. Chest. 1992 Nov. 102(5):1464-9. [Medline].

  53. Neo EN, Haritharan T, Thambidorai CR, Suresh V. Pseudomonas necrotizing fasciitis in an immunocompetent infant. Pediatr Infect Dis J. 2005 Oct. 24 (10):942-3. [Medline].

  54. Obritsch MD, Fish DN, MacLaren R, Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy. 2005 Oct. 25(10):1353-64. [Medline].

  55. Pandey A, Malenie R, Asthana AK. Beta-lactamase producing Pseudomonas aeruginosa in hospitalised patients. Indian J Pathol Microbiol. 2005 Oct. 48(4):530-3. [Medline].

  56. Paul M, Leibovici L. Combination antibiotic therapy for Pseudomonas aeruginosa bacteraemia. Lancet Infect Dis. 2004 Aug. 4(8):519-27. [Medline].

  57. Radford R, Brahma A, Armstrong M, Tullo AB. Severe sclerokeratitis due to Pseudomonas aeruginosa in noncontact-lens wearers. Eye. 2000 Feb. 14 (Pt 1):3-7. [Medline].

  58. Rajashekaraiah KR, Rice TW, Kallick CA. Recovery of Pseudomonas aeruginosa from syringes of drug addicts with endocarditis. J Infect Dis. 1981 Nov. 144(5):482. [Medline].

  59. Roilides E, Butler KM, et al. Pseudomonas Infections in Children with Human Immunodeficiency Virus Infection. Pediatric Infect Dis J. 1992. 11:547-53.

  60. Saiman L. The use of macrolide antibiotics in patients with cystic fibrosis. Curr Opin Pulm Med. 2004 Nov. 10(6):515-23. [Medline].

  61. Schimpff SC, Moody M, Young VM. Relationship of colonization with Pseudomonas aeruginosa to development of Pseudomonas bacteremia in cancer patients. Antimicrobial Agents Chemother. 1970. 10:240-4. [Medline].

  62. Tabbara KF, El-Sheikh HF, Aabed B. Extended wear contact lens related bacterial keratitis. Br J Ophthalmol. 2000 Mar. 84(3):327-8. [Medline].

  63. Tablan OC, Chorba TL, Schidlow DV, et al. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr. 1985 Sep. 107(3):382-7. [Medline].

  64. Taneja N, Meharwal SK, Sharma SK, Sharma M. Significance and characterisation of pseudomonads from urinary tract specimens. J Commun Dis. 2004 Mar. 36(1):27-34. [Medline].

  65. Tsekouras AA, Johnson A, Miller G, Orton HI. Pseudomonas aeruginosa necrotizing fasciitis: a case report. J Infect. 1998 Sep. 37(2):188-90. [Medline].

  66. Tumaliuan JA, Stambouly JJ, Schiff RJ, et al. Pseudomonas pericarditis and tamponade in an infant with human immunodeficency virus infection. Arch Pediatr Adolesc Med. 1997 Feb. 151(2):207-8. [Medline].

  67. Whitehead B, Helms P, Goodwin M, et al. Heart-lung transplantation for cystic fibrosis. 2: Outcome. Arch Dis Child. 1991 Sep. 66(9):1022-6; discussion 1016-7. [Medline].

  68. Wu BY, Peng CT, Tsai CH, Chiu HH. Community-acquired Pseudomonas aeruginosa bacteremia and sepsis in previously healthy infants. Acta Paediatr Taiwan. 1999 Jul-Aug. 40(4):233-6. [Medline].

  69. Yeung CK, Lee KH. Community acquired fulminant Pseudomonas infection of the gastrointestinal tract in previously healthy infants. J Paediatr Child Health. 1998 Dec. 34(6):584-7. [Medline].

  70. Over-the-Counter Topical Antiseptic Products: Drug Safety Communication - FDA Requests Label Changes and Single-Use Packaging to Decrease Risk of Infection. FDA. 11/13/2013. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm374892.htm.

  71. Zegans ME, DiGiandomenico A, Ray K, Naimie A, Keller AE, Stover CK, et al. Association of Biofilm Formation, Psl Exopolysaccharide Expression, and Clinical Outcomes in Pseudomonas aeruginosa Keratitis: Analysis of Isolates in the Steroids for Corneal Ulcers Trial. JAMA Ophthalmol. 2016 Feb 4. [Medline].

Previous
Next
 
Erythematous papulopustules of pseudomonas folliculitis. Courtesy of Mark Welch, MD.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.